Tamtam Try Tamtam free
Dentsply Sirona logo

Dentsply Sirona account plan

dental products technologies solutions

At a glance

Dentsply Sirona makes dental equipment, consumables, implants, aligners and continence care products, with $3,680 million of FY2025 net sales.

Dentsply Sirona describes itself as the world's largest diversified manufacturer of professional dental products and technologies, plus continence care products through Wellspect. It is headquartered in Charlotte, North Carolina, listed on Nasdaq (XRAY) and sells in approximately 140 countries, about two-thirds of its dental products through third-party distributors. FY2025 net sales were $3,680 million, down 3.0% as reported, with a net loss of $598 million after $650 million of impairments. It had approximately 14,000 employees at December 31, 2025. The company is six months into a 24-month Return to Growth action plan led by CEO Dan Scavilla.

Business units

Strategic priorities

Return to Growth action plan
A 24-month plan puts customers first, better execution and investment where growth is greatest; the U.S. is the top priority, with the aim to exit 2026 with U.S. growth.
U.S. commercial reset
Seven new North American distribution agreements were signed this year, quota-carrying field vacancies fell to the mid-single digits from more than 20%, and the MIS sales force is to nearly double by year-end; a new team targets Dental Support Organizations.
Innovation and DS Core
R&D is planned at about 5% of net sales from 2026, focused on DS Core, clinical AI and next-generation intraoral scanners; implants and ortho on DS Core are targeted for late 2027 subject to FDA approval.
Clinical education
Clinical education spend in North America in H2 2026 is six times last year's level, including more than 160 Endo courses.
Cost savings and debt reduction
The 2026 Plan targets approximately $100 million of annualized savings (first set at approximately $120 million), partly reinvested; net debt to EBITDA was 3.4x and debt reduction remains a priority.

Latest results

In Q3 2026 (quarter to September 30, 2026) net sales were $836 million, down 7.6% as reported from $904 million; excluding Byte, planned dealer inventory reductions and one-offs they fell 3.8%. Nine-month sales were $2,614 million, down 3.9%. Gross margin rose to 52.9% from 48.8%, helped by a $39 million inventory estimate change, and the net loss narrowed to $2 million from $427 million. Full-year 2026 guidance was cut to approximately $3.5 billion of sales and adjusted EPS of $1.20-$1.30, from $1.40-$1.50. No 2027 guidance has been given.

Investments and deals

2026 capital expenditures
2026 capex was raised to $165-185 million, covering supply chain equipment, capacity for product innovation, DS Core enhancements and a new global ERP.
2026 restructuring plan
Approved February 24, 2026; $54 million of charges incurred so far, with total charges now expected at $60-65 million.
R&D increase
R&D rose 14.9% to $42 million in Q3 2026 (5.0% of sales), mostly for DS Core, under a new stage-gate product development process.
Wellspect growth
Investment in Wellspect rose 15% to pursue the $7 billion urinary management market, completing the U.S. Surity portfolio.

Challenges and risks

Declining sales and impairments
FY2025 sales fell 3.0% with $650 million of goodwill and intangible impairments; the Implant & Prosthetic Solutions goodwill was fully written off.
Distributor destocking
EMEA distributors are cutting inventory from about 12 weeks to about 8, and Henry Schein accounted for 13% of 2025 net sales, creating concentration and ordering variability.
CAD/CAM and implant pricing pressure
CAD/CAM faces pricing pressure from lower-cost entrants in EMEA and competitive pressure in the U.S.; premium implant volumes are down.
Tariffs and geopolitics
Much of the U.S. equipment is made in Europe; Russia and Ukraine are about 3% of sales, implants are made in two Israeli plants, and Middle East conflict lowered revenue in some markets.
Leverage
Net debt was $2,002 million at end 2025, the credit agreement was amended for covenant flexibility and the quarterly dividend was eliminated from Q1 2026.

What leadership says

“We are making progress, but our results are not yet where they need to be.”

Dan Scavilla, President and Chief Executive Officer · Q3 2026 earnings call, November 5, 2026

“We're making progress, but this is still a turnaround.”

Dan Scavilla, President and Chief Executive Officer · Q2 2026 earnings call, August 6, 2026

“We return to growth, we maximize profitability, and we maximize cash generation.”

John Fortson, EVP and Chief Financial Officer · Q2 2026 earnings call, August 6, 2026

“US remains a top focus, and we are encouraged by the green shoots we are seeing.”

Dan Scavilla, President and Chief Executive Officer · Q3 2026 earnings call, November 5, 2026

Where a supplier can help

Sales enablement and training
Tied to the U.S. commercial reset: hiring, certification and training support for a sales force rebuilding vacancies and nearly doubling MIS reps.
Distributor activation
Tied to the seven new North American distribution agreements and distributor destocking: channel management, incentive and inventory visibility tools.
ERP and finance systems
Tied to the new global ERP in the 2026 capex plan and the new financial consolidation system: implementation and forecasting support.
Software and AI for DS Core
Tied to the R&D push on DS Core and clinical AI: cloud, AI and software engineering partners for connected dentistry.
Cost reduction
Tied to the 2026 Plan savings and debt reduction priority: lean operations, procurement and automation offers that free cash.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Dentsply Sirona?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Dentsply Sirona

What does Dentsply Sirona do?

It develops, manufactures and markets dental equipment, cloud-enabled software, dental consumables, implants and clear aligners, plus continence care products through Wellspect.

What is Dentsply Sirona's revenue?

FY2025 net sales were $3,680 million, down 3.0% as reported. 2026 guidance is approximately $3.5 billion.

How many employees does Dentsply Sirona have?

Approximately 14,000 employees at December 31, 2025, approximately 3,000 of them in the U.S.

What is Dentsply Sirona's strategy?

A 24-month Return to Growth action plan focused on returning the U.S. to growth, sales force and clinical education investment, DS Core innovation, cost savings and debt reduction.

Who leads Dentsply Sirona?

Dan Scavilla is President and Chief Executive Officer, John Fortson is EVP and Chief Financial Officer, and Gregory T. Lucier is Chairman of the Board.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)